Search Results

Quest Diagnostics, a leader in diagnostic information services, released its 2023 Corporate Responsibility Report.

Quest Diagnostics and Allina Health announced a definitive agreement for Quest to acquire select laboratory assets from Allina Health, with the goal to improve access to and the affordability of innovative laboratory services across Minnesota and western Wisconsin.

Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report second quarter 2024 financial results on Tuesday, July 23, 2024, before the market opens.

D&D Pharmatech, Inc., a clinical-stage biotechnology company focused on the development of disease-modifying drugs, announced that the U.S. Food and Drug Administration has granted Fast Track designation for the investigation of DD01 for the treatment of adults with non-alcoholic steatohepatitis, also known as metabolic dysfunction-associated steatohepatitis.

Quest Diagnostics, a leader in diagnostic information services, announced that its Board of Directors declared a quarterly cash dividend of $0.75 per share, payable on July 22, 2024 to shareholders of record of Quest Diagnostics common stock on July 8, 2024.

Quest Diagnostics Incorporated (NYSE: DGX) announced that Jim Davis, Chairman, CEO and President, will speak on the company’s strategy, performance and the latest market developments and trends during a fireside chat at the 2024 Leerink Partners Healthcare Crossroads Conference in Austin, Texas on Wednesday, May 29, 2024, at 10:20 a.m. Eastern Time.

YDS Pharmatech, Inc., a pioneering innovator at a transformative juncture in applying AI to drug discovery, announces its participation in this year’s Bio Investor Forum.

Quest Diagnostics Incorporated, a leading provider of diagnostic information services, announced financial results for the first quarter ended March 31, 2024.